Skip to content
Medical Health Aged Care, Science

$3m federal government grant supports world-first IVF study

23Strands | Virtus Health | Monash University 2 mins read
World-First IVF Study - 23Strands, Virtus health, Monash University

A $3 million federal government grant for a world-first IVF study has been welcomed by the research team partners.

Researchers from Virtus Health, healthtech startup 23Strands and Monash University, are studying how whole genome sequencing can be used to achieve better patient outcomes with IVF medications.

The grant from the government’s Medical Research Future Fund (MRFF) is providing the funding over four years.

James Pyne, Virtus Health CEO said: “The impact of this grant has huge potential to benefit all IVF patients and is a significant step forward for IVF research and innovation. 

Having a better understanding of a patient’s genomic sequencing can help clinicians deliver improved fertility insights, treatments, and personalised medicine, and ultimately better success rates.” said Mr Pyne.

Lead researcher Professor Beverley Vollenhoven from Monash University says the study has the potential to revolutionise the entire landscape of fertility care.

“The groundbreaking collaboration of integrating genomics, artificial intelligence and clinical care aspires to set a new global standard to positively improve women’s responses to IVF medications,” Professor Vollenhoven said.

By understanding how a woman’s genes can affect how they respond to IVF medications, the study’s end goal is to create an AI-driven tool to deliver better targeted doses and improve IVF success rates. 

A recent pilot study by Virtus Health and 23Strands found genetic variations mean every woman has a different response to ovarian stimulation medication.

The MRFF grant will enable the research team to build on these preliminary findings; and conduct a four-year randomised control trial (RCT); the gold standard and most scientifically rigorous assessment method, to help develop a tool for personally targeted dosing of medications.

23Strands co-founder and CEO Mark Grosser said, “This world-first project is special because we will be using new ways to process information about IVF treatments. 23Strands brings innovation that combines data from scientific research, medical records and genetics to deliver tailored personalised medical reports for women. Our world-leading partners will help ensure that this is done in an ethical, safe and effective way.”

A/Prof Vinayak Smith, Head of New Ventures at Virtus Health said: “Virtus Health was the first to develop artificial intelligent embryo selection software. With this new study, we aim to be the first IVF service provider in Australia to offer whole-genome sequencing and AI to augment reproductive decision making and help people achieve their dream of starting a family.


About us:

ABOUT 23STRANDS: 23Strands is delivering the commercial integration of genomics into mainstream healthcare by delivering innovations in bioinformatics, scientific literature analysis and clinical insights based on whole genome sequencing (WGS). 23Strands aims to use these innovations to deliver on the promise of Personalised Medicine and the diagnosis and management of disease.

 

ABOUT VIRTUS HEALTH: Virtus Health brings together leading clinicians, scientists, researchers and support staff to provide the very best in fertility care and related specialised diagnostic and day hospital services. We have developed one of the most successful ARS collaborations in the world. With 126 of the world’s leading fertility specialists supported by over 1300 professional staff, we are the largest network and provider of fertility services in Australia, Ireland and Denmark, Singapore and UK

Media

More from this category

  • Education Training, Medical Health Aged Care
  • 23/02/2024
  • 10:27
Charles Darwin University

New short courses to give insight into emergency and disaster health

In a time of environmental disasters and ongoing threats of disease outbreaks, a new suite of micro-credential courses will give students access to the…

  • Contains:
  • Medical Health Aged Care
  • 23/02/2024
  • 10:10
Dementia Australia

ONE WEEK TO GO until Illawarra’s Memory Walk & Jog!

With only a few sleeps to go walkers, joggers and runners are gearing up to participate in the 2024 Illawarra Memory Walk & Jog. More than 500 people have already signed-up to take part – but there’s always room for more with online registrations still open, or sign-up on the day of the event. Dementia Australia CEO Maree McCabe AM said it is fantastic to see the Illawarra community throwing their support behind Memory Walk & Jog. “As we prepare to host Memory Walk & Jog on Sunday 3 March at Wollongong's Lang Park for another successful year, we hope…

  • Contains:
  • Medical Health Aged Care, Research Development
  • 23/02/2024
  • 09:38
La Trobe University

New lead in gut health research

Wednesday February 22, 2024 La Trobe University researchers have identified a protein that is integral to gut health, providing an important lead in the search for a treatment for people with Inflammatory Bowel Disease (IBD). Research published in Communications Biology, shows for the first time that in mice, the removal of the protein BECLIN1 causes a condition with similarities to IBD. The study shows that removing BECLIN1 causes problems in the internal “trafficking” pathways of the epithelial cells which line the intestine, leading to a disruption of the protective barrier the cells create. This disruption can allow bacteria to enter…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.